GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (TSX:LABS) » Definitions » Deferred Policy Acquisition Costs

MediPharm Labs (TSX:LABS) Deferred Policy Acquisition Costs


View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


MediPharm Labs Business Description

Industry
Traded in Other Exchanges
Address
151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.
Executives
Keith Strachan Director
Gregory Edison Hunter Senior Officer
David Pidduck Director, Senior Officer
Bryan Howcroft Director, Senior Officer
Patrick Mccutcheon Director
Warren Everitt Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Etf Managers Trust 10% Security Holder
Christopher David Taves Director
Sybil Taylor Senior Officer
Braden Fenske Senior Officer
David John Mayers Senior Officer